The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis

• Conditions: Type 2 Diabetes

• Registration Number: NCT04424706
• Lead Sponsor: Majianhua

Brief Summary

The study will assess the serum expression of MMP-9 in normal people, type 2 diabetic patients and type 2 diabetic patients with atherosclerosis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-06
• Study First Submitted: 2020-06-07
• Study First Submitted QC: 2020-06-08
• Last Update Submitted: 2020-06-08
• Study First Posted: 2020-06-11
• Last Update Posted: 2020-06-11
• Study Start: 2020-06-30
• Primary Completion: 2020-11-30
• Study Completion: 2020-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• volunteer to participate and be able to sign informed consent prior to the trial.
• patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic criteria, have not used any drugs.
• The patients have completed carotid ultrasound during hospitalization.

Exclusion Criteria

• patients with any antidiabetic drugs.
• impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.
• drug abuse and alcohol dependence in the past 5 years.
• systemic hormone therapy was used in the last three months.
• patients with infection and stress within 4 weeks.
• any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
total MMP-9 levels	6 months	the different group of total MMP-9 levels

Trial Locations

Locations (1)

Nanjing First Hospital; 🇨🇳 Nanjing, Jiangsu, China